The practical procedures of digestive tract decontamination and prophylaxis of bacterial infection in granulocytopenic patients are debated. Fluoroquinolones are active against Gram-negative bacilli and have few side-effects. Pefloxacin was administered prophylactically to patients with cancer and granulocytopenia. None of them developed Gram-negative septicaemia, but 2 cases of streptococcal septicaemia were observed. The drug was well tolerated by all patients except one. Studies are currently in progress to try to reduce the incidence of septicaemia caused by Gram-positive cocci, using pefloxacin combined with penicillin.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe
(See the editorial commentary by Zinner on pages 1094–5) Background. Fluoroquinolone prophylaxis dur...
Contains fulltext : 47915_pub.pdf (publisher's version ) (Closed access) ...
SummaryBackgroundThe routine use of fluoroquinolone prophylaxis in patients with neutropenia and hem...
Bacterial infections remain a major source of morbidity and mortality in neutropenic patients. There...
Fluoroquinolones are the most attractive agents for prophylactic use in neutropenic cancer patients,...
We conducted a two-part meta-analysis to assess the effectiveness of fluoroquinolones for preventing...
We conducted a two-part meta-analysis to assess the effectiveness of fluoroquinolones for pre-ventin...
Infections are a major cause of morbidity and mortality among immune-compromised patients. The autho...
The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial an...
Background: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is cont...
We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bac...
Infections are a major cause of morbidity and mortality among immunocompromised patients. This repor...
Bacterial infections remain a frequent cause of morbidity and mortality in cancer patients with gran...
The use of oral prophylactic antibiotics in oncology patients is still a matter of debate. A systema...
The benefits of oral prophylaxis for neutropenia have remained controversial up to now. We evaluated...
(See the editorial commentary by Zinner on pages 1094–5) Background. Fluoroquinolone prophylaxis dur...
Contains fulltext : 47915_pub.pdf (publisher's version ) (Closed access) ...
SummaryBackgroundThe routine use of fluoroquinolone prophylaxis in patients with neutropenia and hem...
Bacterial infections remain a major source of morbidity and mortality in neutropenic patients. There...
Fluoroquinolones are the most attractive agents for prophylactic use in neutropenic cancer patients,...
We conducted a two-part meta-analysis to assess the effectiveness of fluoroquinolones for preventing...
We conducted a two-part meta-analysis to assess the effectiveness of fluoroquinolones for pre-ventin...
Infections are a major cause of morbidity and mortality among immune-compromised patients. The autho...
The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial an...
Background: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is cont...
We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bac...
Infections are a major cause of morbidity and mortality among immunocompromised patients. This repor...
Bacterial infections remain a frequent cause of morbidity and mortality in cancer patients with gran...
The use of oral prophylactic antibiotics in oncology patients is still a matter of debate. A systema...
The benefits of oral prophylaxis for neutropenia have remained controversial up to now. We evaluated...
(See the editorial commentary by Zinner on pages 1094–5) Background. Fluoroquinolone prophylaxis dur...
Contains fulltext : 47915_pub.pdf (publisher's version ) (Closed access) ...
SummaryBackgroundThe routine use of fluoroquinolone prophylaxis in patients with neutropenia and hem...